, Volume 6, Issue 1, pp 28–42

Multifunctional drugs for head injury

Review Article


Traumatic brain injury (TBI) remains one of the leading causes of mortality and morbidity worldwide in individuals under the age of 45 years, and, despite extensive efforts to develop neuroprotective therapies, there has been no successful outcome in any trial of neuroprotection to date. In addition to recognizing that many TBI clinical trials have not been optimally designed to detect potential efficacy, the failures can be attributed largely to the fact that most of the therapies investigated have been targeted toward an individual injury factor. The contemporary view of TBI is that of a very heterogenous type of injury, one that varies widely in etiology, clinical presentation, severity, and pathophysiology. The mechanisms involved in neuronal cell death after TBI involve an interaction of acute and delayed anatomic, molecular, biochemical, and physiological events that are both complex and multifaceted. Accordingly, neuropharmacotherapies need to be targeted at the multiple injury factors that contribute to the secondary injury cascade, and, in so doing, maximize the likelihood of a successful outcome. This review focuses on a number of such multifunctional compounds that have shown considerable success in experimental studies and that show maximum promise for success in clinical trials.

Key Words

Neurotrauma statins progesterone erythropoietin cyclosporin toll-like receptors magnesium dexanabinol bradykinin substance P minocycline thyrotropin releasing hormone 


  1. 1.
    Finfer SR, Cohen J. Severe traumatic brain injury. Resuscitation 2001;48:77–90.PubMedGoogle Scholar
  2. 2.
    Kraus JF. Epidemiology of head injury. In: Cooper PR, editor. Head injury. 3rd ed. Baltimore: Williams & Wilkins, 1993:1–25.Google Scholar
  3. 3.
    Hillier SL, Hiller JE, Metzer J. Epidemiology of traumatic brain injury in South Australia. Brain Injury 1997;11:649–659.PubMedGoogle Scholar
  4. 4.
    Mendelow AD, Crawford PJ. Primary and secondary brain injury. In: Reilly PL, Bullock R, editors. Head injury: pathophysiology and management of severe closed injury. 1st ed. London: Chapman & Hall, 1997: 72–88.Google Scholar
  5. 5.
    McIntosh TK, Smith DH, Meaney DF, Kotapka MJ, Gennarelli TA, Graham DI. Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab Invest 1996;74: 315–342.PubMedGoogle Scholar
  6. 6.
    Maas AI. Neuroprotective agents in traumatic brain injury. Expert Opin Investig Drugs 2001;10:753–767.PubMedGoogle Scholar
  7. 7.
    Narayan RK, Michel ME, Ansell B, et al.; Clinical Trials in Head Injury Study Group. J Neurotrauma 2002;19:503–557.PubMedGoogle Scholar
  8. 8.
    Tolias CM, Bullock MR. Critical appraisal of neuroprotection trials in head injury: what have we learned? NeuroRx 2004;1:71–79.PubMedGoogle Scholar
  9. 9.
    Faden AI. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition? Curr Opin Neurol 2002;15:707–712.PubMedGoogle Scholar
  10. 10.
    Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360–1362.PubMedGoogle Scholar
  11. 11.
    Hickenbottom SL, Grotta J. Neuroprotective therapy. Semin Neurol 1998;18:485–492.PubMedGoogle Scholar
  12. 12.
    Gentile NT, McIntosh TK. Antagonists of excitatory amino acids and endogenous opioid peptides in the treatment of experimental central nervous systems injury. Ann Emerg Med 1993;22:1028–1035.PubMedGoogle Scholar
  13. 13.
    Willis C, Lybrand S, Bellamy N. Excitatory amino acid inhibitors for traumatic brain injury. Cochrane Database Syst Rev. 2004; (l):CD003986.Google Scholar
  14. 14.
    Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989;244:798–800.PubMedGoogle Scholar
  15. 15.
    Lea PM 4th, Faden AI. Traumatic brain injury: developmental differences in glutamate receptor response and the impact on treatment. Ment Retard Dev Disabil Res Rev 2001;7:235–248.PubMedGoogle Scholar
  16. 16.
    Haeberlein SL. Mitochondrial function in apoptotic neuronal cell death. Neurochem Res 2004;29:521–530.PubMedGoogle Scholar
  17. 17.
    Signoretti S, Marmarou A, Aygok GA, Fatouros PP, Portella G, Bullock RM. Assessment of mitochondrial impairment in traumatic brain injury using high-resolution proton magnetic resonance spectroscopy. J Neurosurg 2008;108:42–52.PubMedGoogle Scholar
  18. 18.
    Petronilli V, Penzo D, Scorrano L, Bemardi P, Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death: correlation with the duration of pore openings in situ. J Biol Chem 2001;276:12030–12034.PubMedGoogle Scholar
  19. 19.
    Hansson MJ, Månsson R, Mattiasson G, et al. Brain-derived respiring mitochondria exhibit homogeneous, complete and cyclosporin-sensitive permeability transition. J Neurochem 2004;89:715–729.PubMedGoogle Scholar
  20. 20.
    Fiskum G. Mitochondrial participation in ischemic and traumatic neural cell death. J Neurotrauma 2000;17:843–855.PubMedGoogle Scholar
  21. 21.
    Fiskum G. Mechanisms of neuronal death and neuroprotection. J Neurosurg Anesthesiol 2004;16:108–110.PubMedGoogle Scholar
  22. 22.
    Mattiasson G, Friberg H, Hansson M, Elmér E, Wieloch T. Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation. J Neurochem 2003;87:532–544.PubMedGoogle Scholar
  23. 23.
    Lemasters JJ, Nieminen AL, Qian T, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998;1366:177–196.PubMedGoogle Scholar
  24. 24.
    Xiong Y, Gu Q, Peterson PL, Muizelaar JP, Lee CP. Mitochondrial dysfunction and calcium pertubation induced by traumatic brain injury. J Neurotrauma 1997;14:23–34.PubMedGoogle Scholar
  25. 25.
    Clausen T, Zauner A, Levasseur JE, Rice AC, Bullock R. Induced mitochondrial failure in the feline brain: implications for understanding acute post-traumatic metabolic events. Brain Res 2001;908:35–48.PubMedGoogle Scholar
  26. 26.
    Cernak I, Savic VJ, Kotur J, Prokic V, Veljovic M, Grbovic D. Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans. J Neurotrauma 2000;17:53–68.PubMedGoogle Scholar
  27. 27.
    Ikeda Y, Long DM. The molecular basis of brain injury and brain edema: the role of oxygen free radicals. Neurosurgery 1990;27:1–11.PubMedGoogle Scholar
  28. 28.
    Lewén A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma 2000;17: 871–890.PubMedGoogle Scholar
  29. 29.
    Shohami E, Beit-Yannai E, Horowitz M, Kohen R. Oxidative stress in closed-head injury: brain antioxidant capacity as an indicator of functional outcome. J Cereb Blood Flow Metab 1997;17:1007–1019.PubMedGoogle Scholar
  30. 30.
    Hall ED, Yonkers PA, Andrus PK, Cox JW, Anderson DK. Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J Neurotrauma 1992;9:S425-S442.PubMedGoogle Scholar
  31. 31.
    Marklund N, Clausen F, Lewander T, Hillered L. Monitoring of reactive oxygen species production after traumatic brain injury in rats with microdialysis and the 4-hydroxybenzoic acid trapping method. J Neurotrauma 2001;18: 1217–1227.PubMedGoogle Scholar
  32. 32.
    Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T. Modulation of immune response by head injury. Injury 2007;38:1360–1362.Google Scholar
  33. 33.
    Israelsson C, Bengtsson H, Kylberg A, et al. Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury. J Neurotrauma 2008;25:959–974.PubMedGoogle Scholar
  34. 34.
    Craft JM, Watterson DM, Van Eldik LJ. Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets 2005;9:887–900.PubMedGoogle Scholar
  35. 35.
    Habgood MD, Bye N, Dziegielewska KM, et al. Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci 2007;25:231–238.PubMedGoogle Scholar
  36. 36.
    Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004;16:1–13.PubMedGoogle Scholar
  37. 37.
    Nimmo AJ, Cernak I, Heath DL, Hu X, Bennett CJ, Vink R. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides 2004;38:40–47.PubMedGoogle Scholar
  38. 38.
    Krizanac-Bengez L, Mayberg MR, Janigro D. The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis [sic] and pathophysiology. Neurol Res 2004;26:846–853.PubMedGoogle Scholar
  39. 39.
    Klatzo I. Brain Edema. In: Odom GL, editor. Central nervous system trauma research status report. Washington, DC: National Institutes of Health, 1979:110–112.Google Scholar
  40. 40.
    Baskaya MK, Dogan A, Rao AM, Dempsey RJ. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg 2000;92:448–452.PubMedGoogle Scholar
  41. 41.
    Kimelberg HK. Current concepts of brain edema: review of laboratory investigations. J Neurosurg 1995;83: 1051–1059.PubMedGoogle Scholar
  42. 42.
    Stover JF, Unterberg AW. Increased cerebrospinal fluid glutamate and taurine concentrations are associated with traumatic brain edema formation in rats. Brain Res 2000;875:51–55.PubMedGoogle Scholar
  43. 43.
    Duvdevani R, Roof RL, Fulop Z, Hoffman SW, Stein DG. Blood-brain barrier breakdown and edema formation following frontal cortical contusion: does hormonal status play a role? J Neurotrauma 1995;12:65–75.PubMedGoogle Scholar
  44. 44.
    Graham DI. Neuropathology of head injury. In: Narayan RK, Wilberger JE Jr, Povlishock JT, editors. Neurotrauma. New York: McGraw-Hill, 1996.Google Scholar
  45. 45.
    Treggiari MM, Schutz N, Yanez ND, Romand JA. Role of intracranial pressure values and patterns in predicting outcome in traumatic brain injury: a systematic review. Neurocrit Care 2007;6:104–112.PubMedGoogle Scholar
  46. 46.
    Carter BG, Butt W, Taylor A. ICP and CPP: excellent predictors of long term outcome in severely brain injured children. Childs Nerv Syst 2008;24:245–251.PubMedGoogle Scholar
  47. 47.
    Walberer M, Ritschel N, Nedelmann M, et al. Aggravation of infarct formation by brain swelling in a large territorial stroke: a target for neuroprotection? J Neurosurg 2008;109:287–293.PubMedGoogle Scholar
  48. 48.
    Reilly PL. Management of intracranial pressure and cerebral perfusion. In: Reilly PL, Bullock R, Head injury: pathophysiology and management of severe closed injury. 1st ed. London: Chapman & Hall, 1997:385–406.Google Scholar
  49. 49.
    Reiss AB, Wirkowski E. Role of HMG-CoA reductase inhibitors in neurological disorders: progress to date. Drugs 2007;67:2111–2120.PubMedGoogle Scholar
  50. 50.
    Rajanikant GK, Zemke D, Kassab M, Majid A. The therapeutic potential of statins in neurological disorders. Curr Med Chem 2007;14:103–112.PubMedGoogle Scholar
  51. 51.
    Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/ Rho-kinase and Akt pathways. Circulation 2002;105:1756–1759.PubMedGoogle Scholar
  52. 52.
    Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 2003;144:681–692.PubMedGoogle Scholar
  53. 53.
    Delanty N, Vaughan CJ, Sheehy N. Statins and neuroprotection. Expert Opin Investig Drugs 2001;10:1847–1853.PubMedGoogle Scholar
  54. 54.
    Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003;58: 719–731.PubMedGoogle Scholar
  55. 55.
    Zacco A, Togo J, Spence K, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003;23:11104–11111.PubMedGoogle Scholar
  56. 56.
    Bösel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 2005;92:1386–1398.PubMedGoogle Scholar
  57. 57.
    Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, Eisel UL. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis 2008;13:111–122.PubMedGoogle Scholar
  58. 58.
    Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743–751.PubMedGoogle Scholar
  59. 59.
    Lu D, Mahmood A, Goussev A, et al. Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. J Neurosurg 2004;101:813–821.PubMedGoogle Scholar
  60. 60.
    Lu D, Qu C, Goussev A, et al. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma 2007;24: 1132–1146.PubMedGoogle Scholar
  61. 61.
    Franke C, Noldner M, Abdel-Kader R, et al. Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis 2007;25:438–445.PubMedGoogle Scholar
  62. 62.
    Pannu R, Christic DK, Barbosa E, Singh I, Singh AK. Posttrauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem 2007;101:182–200.PubMedGoogle Scholar
  63. 63.
    Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 2007;13:208–213.PubMedGoogle Scholar
  64. 64.
    Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2008 Aug. 20 [Epub ahead of print].Google Scholar
  65. 65.
    Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999;22:410–416.PubMedGoogle Scholar
  66. 66.
    Komeyev A, Costa E. Allopregnanolone (THP) mediates anesthetic effects of progesterone in rat brain. Horm Behav 1996;30:37–43.Google Scholar
  67. 67.
    Rodgers RJ, Johnson NJ. Behaviorally selective effects of neuroactive steroids on plus-maze anxiety in mice. Pharmacol Biochem Behav 1998;59:221–232.PubMedGoogle Scholar
  68. 68.
    Frye CA, Walf AA, Rhodes ME, Hamey JP. Progesterone enhances motor, anxiolytic, analgesic, and antidepressive behavior of wild-type mice, but not those deficient in type 1 5α-reductase. Brain Res 2004;1004:116–124.PubMedGoogle Scholar
  69. 69.
    Gonzalez Deniselle MC, Costa JJL, Gonzalez SL, et al. Basis of progesterone protection in spinal cord neurodegeneration. J Steroid Biochem Mol Biol 2002;83:199–209.PubMedGoogle Scholar
  70. 70.
    Kumon Y, Soon CK, Tompkins P, Stevens Al, Sakaki S, Loftus M. Neuroprotective effect of postischemic administration of progesterone in spontaneously hypertensive rats with focal cerebral ischemia. J Neurosurg 2000;92:848–852.PubMedGoogle Scholar
  71. 71.
    Jiang N, Chopp M, Stein D, Feit H. Progesterone is neuroprotective after transient middle cerebral occlusion in male rats. Brain Res 1996;735:101–107.PubMedGoogle Scholar
  72. 72.
    Vongher J, Frye C. Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration. Pharmacol Biochem Behav 1999;64:777–785.PubMedGoogle Scholar
  73. 73.
    Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma 2000;17:367–388.PubMedGoogle Scholar
  74. 74.
    Ogata T, Nakamura Y, Tsuji K, Shibata T, Kataoka K. Steroid hormones protect spinal cord neurons from glutamate toxicity. Neuroscience 1993;55:445–449.PubMedGoogle Scholar
  75. 75.
    Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6:2311–2322.PubMedGoogle Scholar
  76. 76.
    Thomas AJ, Nockles RP, Hiu QP, Shaffrey CI, Chopp M. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine 1999;24:2134–2138.PubMedGoogle Scholar
  77. 77.
    Labombarda F, Gonzalez SL, Gonzalez Deniselle MC, Guennoun R, Schumacher M, de Nicola AF. Cellular basis for progesterone neuroprotection in the injured spinal cord. J Neurotrauma 2002;19:343–355.PubMedGoogle Scholar
  78. 78.
    Gonzalez-Vidal MD, Cervera-Gaviria M, Ruelas R, Escobar A, Moralí G, Cervantes M. Progesterone: protective effects on the cat hippocampal neuronal damage due to acute global cerebral ischemia. Arch Med Res 1998;28:117–124.Google Scholar
  79. 79.
    Koenig HL, Gong WH, Pelissier P. Role of progesterone in peripheral nerve repair. Rev Reprod 2000;5:189–199.PubMedGoogle Scholar
  80. 80.
    Gruber CJ, Huber JC. Differential effects of progestins on the brain. Maturitas 2003;46 Suppl 1: S71-S75.PubMedGoogle Scholar
  81. 81.
    Roof RL, Zhang Q, Glasier MM, Stein DG. Gender-specific impairment on Morris water maze task after entorhinal cortex lesion. Behav Brain Res 1993;57:47–51.PubMedGoogle Scholar
  82. 82.
    Roof RL, Duvdevani R, Braswell L, Stein DG. Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp Neurol 1994;129:64–69.PubMedGoogle Scholar
  83. 83.
    Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol 2002;178:59–67.PubMedGoogle Scholar
  84. 84.
    He J, Hoffman SW, Stein DG. Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. Restor Neurol Neurosci 2004;22:19–31.PubMedGoogle Scholar
  85. 85.
    Roof RL, Hoffman SW, Stein DG. Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol Chem Neuropathol 1997;31:1–11.PubMedGoogle Scholar
  86. 86.
    Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurones. J Neurochem 1996;66:1836–1844.PubMedGoogle Scholar
  87. 87.
    Smith SS. Progesterone administration attenuates excitatory amino acid responses of cerebellar Purkinje cells. Neuroscience 1991;42:309–320.PubMedGoogle Scholar
  88. 88.
    Cai W, Zhu Y, Furuya K, Li Z, Sokabe M, Chen L. Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacology 2008;55:127–138.PubMedGoogle Scholar
  89. 89.
    Djebaili M, Hoffman SW, Stein DG. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience 2004;123:349–359.PubMedGoogle Scholar
  90. 90.
    O’Connor CA, Cernak I, Johnson F, Vink R. Effects of progesterone on neurologic and morphologic outcome following diffuse traumatic brain injury in rats. Exp Neurol 2007;205:145–153.PubMedGoogle Scholar
  91. 91.
    Pettus EH, Wright DW, Stein DG, Hoffman SW. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res 2005;1049:112–119.PubMedGoogle Scholar
  92. 92.
    Roof RL, Duvdevani R, Stein DG. Progesterone treatment attenuates brain edema following contusion injury in male and female rats. Restor Neurol Neurosci 1992;4:425–427.Google Scholar
  93. 93.
    O’Connor CA, Cernak I, Vink R. Both estrogen and progesterone attenuate edema formation following diffuse traumatic brain injury in rats. Brain Res 2005;1062:171–174.PubMedGoogle Scholar
  94. 94.
    Roof RL, Duvdevani R, Heybum JW, Stein DG. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp Neurol 1996;138:246–251.PubMedGoogle Scholar
  95. 95.
    Wright DW, Bauer ME, Hoffman SW, Stein DG. Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J Neurotrauma 2001;18:901–909.PubMedGoogle Scholar
  96. 96.
    Limmroth V, Lee WS, Moskowitz MA. GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br J Pharmacol 1996;117:99–104.PubMedGoogle Scholar
  97. 97.
    Kuebler JF, Yokoyama Y, Jarrar D, et al. Administration of progesterone after trauma and hemorrhagic shock prevents hepatocellular injury. Arch Surg 2003;138:727–734.PubMedGoogle Scholar
  98. 98.
    Kuebler JF, Jarrar D, Bland KI, Rue L, 3rd, Wang P, Chaudry IH. Progesterone administration after trauma and hemorrhagic shock improves cardiovascular responses. Crit Care Med 2003;31: 1786–1793.PubMedGoogle Scholar
  99. 99.
    Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007;49:391–402, 402.e2.PubMedGoogle Scholar
  100. 100.
    Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 2008;12:R61.PubMedGoogle Scholar
  101. 101.
    Lapchak PA. Carbamylated erythropoietin to treat neuronal injury: new development strategies. Expert Opin Investig Drugs 2008;17:1175–1186.PubMedGoogle Scholar
  102. 102.
    Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000;97:10526–10531.PubMedGoogle Scholar
  103. 103.
    Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, Iacopino DG. Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res 2007;1182:99–105.PubMedGoogle Scholar
  104. 104.
    Cherian L, Goodman JC, Robertson C. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther 2007;322:789–794.PubMedGoogle Scholar
  105. 105.
    Elfar JC, Jacobson JA, Puzas JE, Rosier RN, Zuscik MJ. Erythropoietin accelerates functional recovery after peripheral nerve injury. J Bone Joint Surg Am 2008;90:1644–1653.PubMedGoogle Scholar
  106. 106.
    Xiong Y, Lu D, Qu C, et al. Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. J Neurosurg 2008;109:510–521.PubMedGoogle Scholar
  107. 107.
    Yuan RR, Li WP, Menonna J, Maeda Y, Dowling PC. Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators 2007: International Application Number PCT/ 1B2006/003581. Patent Publication Number WO2007052154 (A2). Available at: KC=A2&date=20070510&NR=2007052154A2&DB=EPODOC&locale=en_EP&CC=WO&FT=D.Google Scholar
  108. 108.
    King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, Beazley LD. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol 2007;205:48–55.PubMedGoogle Scholar
  109. 109.
    Xiong Y, Mahmood A, Lu D, et al. Histological and functional outcomes after traumatic brain injury in mice null for the erythropoietin receptor in the central nervous system. Brain Res 2008;1230:247–257.PubMedGoogle Scholar
  110. 110.
    Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 2005;94:819–827.PubMedGoogle Scholar
  111. 111.
    Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001;48:1393–1399.PubMedGoogle Scholar
  112. 112.
    Wells JE, Huribert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003;126:1628–1637.PubMedGoogle Scholar
  113. 113.
    Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A 2004;101:3071–3076.PubMedGoogle Scholar
  114. 114.
    Yune TY, Lee JY, Jung GY, et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 2007;27:7751–7761.PubMedGoogle Scholar
  115. 115.
    Fan LW, Pang Y, Lin S, et al. Minocycline reduces lipopolysaccharide-induced neurological dysfunction and brain injury in the neonatal rat. J Neurosci Res 2005;82:71–82.PubMedGoogle Scholar
  116. 116.
    Bye N, Habgood MD, Callaway JK, et al. Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Exp Neurol 2007;204:220–233.PubMedGoogle Scholar
  117. 117.
    Carty ML, Wixey JA, Colditz PB, Buller KM. Post-insult minocycline treatment attenuates hypoxia-ischemia-induced neuroinflammation and white matter injury in the neonatal rat: a comparison of two different dose regimens. Int J Dev Neurosci 2008;26:477–485.PubMedGoogle Scholar
  118. 118.
    Chung KF. Drugs to suppress cough. Expert Opin Investig Drugs 2005;14:19–27.PubMedGoogle Scholar
  119. 119.
    Rodi D, Couture R, Ongali B, Simonato M. Targeting kinin receptors for the treatment of neurological diseases. Curr Pharm Des 2005;11:1313–1326.PubMedGoogle Scholar
  120. 120.
    Noda M, Kariura Y, Pannasch U, et al. Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J Neurochem 2007;101:397–410.PubMedGoogle Scholar
  121. 121.
    Kaplanski J, Pruneau D, Asa I, et al. LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J Neurotrauma 2002;19:953–964.PubMedGoogle Scholar
  122. 122.
    Marmarou A, Nichols J, Burgess J, et al.; American Brain Injury Consortium Study Group. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. J Neurotrauma 1999;16:431–444.PubMedGoogle Scholar
  123. 123.
    Maggi CA. Pharmacology of the efferent function of primary sensory neurons. In: Geppetti P, Holzer P, editors. Neurogenic inflammation. Boca Raton, FL: CRC Press, 1996.Google Scholar
  124. 124.
    Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640–1645.PubMedGoogle Scholar
  125. 125.
    Nessler S, Stadelmann C, Bittner A, et al. Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist: a putative role for substance P in CNS inflammation. J Neuroimmunol 2006;179:1–8.PubMedGoogle Scholar
  126. 126.
    Reardon K, Heath DL, Nimmo AJ, Vink R, Whitfield K. Inhibition of neurogenic inflammation attenuates the inflammatory response following traumatic brain injury in rats. In: 7th International Neurotrauma Symposium. Bologna: Medimond International Proceedings, 2004:115–118.Google Scholar
  127. 127.
    Donkin JJ, Turner RJ, Hassan I, Vink R. Substance P in traumatic brain injury. Prog Brain Res 2007;161:97–109.PubMedGoogle Scholar
  128. 128.
    Alvaro G, Di Fabio R. Neurokinin 1 receptor antagonists: current prospects. Curr Opin Drug Discov Devel 2007;10:613–621.PubMedGoogle Scholar
  129. 129.
    Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675–680.PubMedGoogle Scholar
  130. 130.
    Marsh BJ, Stenzel-Poore MP. Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. Curr Opin Pharmacol 2008;8:8–13.PubMedGoogle Scholar
  131. 131.
    Van Noort JM, Bsibsi M. Use of TLR3 agonists for treatment of neurodegenerative disorders 2007, Patent Application Number WO2007089151 [Available at: jsp?wo=2007089151].Google Scholar
  132. 132.
    Boivin N, Sergeric Y, Rivest S, Boivin G. Effect of pretreatment with Toll-like receptor agonists in a mouse model of Herpes simplex virus type 1 encephalitis. J Infect Dis 2008;198:664–672.PubMedGoogle Scholar
  133. 133.
    Pop E. Dexanabinol Pharmos. Curr Opin Investig Drugs 2000;1:494–503.PubMedGoogle Scholar
  134. 134.
    Darlington CL. Dexanabinol: a novel cannabinoid with neuroprotective properties. IDrugs 2003;6:976–979.PubMedGoogle Scholar
  135. 135.
    Shohami E, Novikov M, Mechoulam R. A nonpsychotropic cannabinoid, HU-211, has cerebrovascular effects after closed head injury in the rat. J Neurotrauma 1993;10:109–119.PubMedGoogle Scholar
  136. 136.
    Belayev L, Busto R, Zhao W, Ginsberg MD. HU-211, a novel noncompetitive N-methyl-d-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke 1995;26:2313–2319; discussion 2319–2320.PubMedGoogle Scholar
  137. 137.
    Feigenbaum JJ, Bergmann F, Richmond SA, et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-d-aspartate receptor blocker. Proc Natl Acad Sci U S A 1989;86:9584–9987.PubMedGoogle Scholar
  138. 138.
    Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A. Neuroprotectant and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol 1995;283:19–29.PubMedGoogle Scholar
  139. 139.
    Shohami E, Gallily R, Mechoulam R, Bass R, Ben Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J Neuroimmunol 1997;72:169–177.PubMedGoogle Scholar
  140. 140.
    Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002;8:58–61.PubMedGoogle Scholar
  141. 141.
    Knoller N, Levi L, Shoshan I, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med 2002;30:548–554.PubMedGoogle Scholar
  142. 142.
    Maas AI, Murray G, Henney H 3rd, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006;5:38–45.PubMedGoogle Scholar
  143. 143.
    Vink R, Nimmo AJ. Novel therapies in development for the treatment of traumatic brain injury. Expert Opin Investig Drugs 2002;11:1375–1386.PubMedGoogle Scholar
  144. 144.
    Hoane MR. Assessment of cognitive function following magnesium therapy in the traumatically injured brain. Magnes Res 2007;20:229–236.PubMedGoogle Scholar
  145. 145.
    Meloni BP, Zhu H, Knuckey NW. Is magnesium neuroprotective following global and focal cerebral ischaemia? A review of published studies. Magnes Res 2006;19:123–137.PubMedGoogle Scholar
  146. 146.
    Haupt H, Scheibe F, Mazurek B. Therapeutic efficacy of magnesium in acoustic trauma in the guinea pig. ORL J Otorhinolaryngol Relat Spec 2003;65:134–139.PubMedGoogle Scholar
  147. 147.
    Hoane MR, Knotts AA, Akstulewicz SL, Aquilano M, Means LW. The behavioral effects of magnesium therapy on recovery of function following bilateral anterior medial cortex lesions in the rat. Brain Res Bull 2003;15: 105–114.Google Scholar
  148. 148.
    Türkyilmaz C, Türkyilmaz Z, Atalay Y, Söylemezoglu F, Celasun B. Magnesium pre-treatment reduces neuronal apoptosis in newborn rats in hypoxia-ischemia. Brain Res 2002;955:133–137.PubMedGoogle Scholar
  149. 149.
    Tang YN, Zhao FL, Ye HM. Expression of caspase-3 mRNA in the hippocampus of seven-day-old hypoxic-ischemic rats and the mechanism of neural protection with magnesium sulfate [In Chinese]. Zhonghua Er Ke Za Zhi 2003;41:212–214.PubMedGoogle Scholar
  150. 150.
    Gee JB 2nd, Corbett RJ, Perlman J, Laptook AR. The effects of systemic magnesium sulfate infusion on brain magnesium concentrations and energy state during hypoxia-ischemia in newborn miniswine. Pediatr Res 2004;55: 93–100.PubMedGoogle Scholar
  151. 151.
    Lee JS, Han YM, Yoo do S, et al. A molecular basis for the efficacy of magnesium treatment following traumatic brain injury in rats. J Neurotrauma 2004;21:549–561.PubMedGoogle Scholar
  152. 152.
    Xu M, Dai W, Deng X. Effects on magnesium sulfate on brain mitochondrial respiratory function in rats after experimental traumatic brain injury. Chin J Traumatol 2002;5:361–364.PubMedGoogle Scholar
  153. 153.
    Sang N, Meng Z. Blockade by magnesium of sodium currents in accutely isolated hippocampal CA1 neurons of rat. Brain Res 2002;18:218–221.Google Scholar
  154. 154.
    Okiyama K, Smith DH, Gennarelli TA, Simon RP, Leach M, McIntosh TK. The sodium channel blocker and glutamate release inhibitor BW1003C87 and magnesium attenuate regional cerebral edema following experimental brain injury in the rat. J Neurochem 1995;64:802–809.PubMedGoogle Scholar
  155. 155.
    Kahraman S, Ozgurtas T, Kayali H, Atabey C, Kutluay T, Timurkaynak E. Monitoring of serum ionized magnesium in neurosurgical intensive care unit: preliminary results. Clin Chem Acta 2003;334:211–215.Google Scholar
  156. 156.
    van den Burgh WM, Algra A, van der Sprenkel JW, Tullenken CA, Rinkel GJ. Hypomagnesia after aneurysmal subarachnoid hemorrhage. Neurosurgery 2003;52:276–281.Google Scholar
  157. 157.
    Stippler M, Fischer MR, Puccio AM, et al. Serum and cerebrospinal fluid magnesium in severe traumatic brain injury outcome. J Neurotrauma 2007;24:1347–1354.PubMedGoogle Scholar
  158. 158.
    Kafadar AM, Sanus GZ, Is M, et al. Prolonged elevation of magnesium in the cerebrospinal fluid of patients with severe head injury. Neurol Res 2007;29:824–829.PubMedGoogle Scholar
  159. 159.
    Heath DL, Vink R. Subdural hematoma following traumatic brain injury causes a secondary decline in brain free magnesium concentration. J Neurotrauma 2001;18:465–469.PubMedGoogle Scholar
  160. 160.
    Altura BM, Kostellow AB, Zhang A, et al. Expression of the nuclear factor-κB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg2+ in aortic and cerebral vascular smooth muscle cells: possible links to hypertension, atherogenesis and stroke. Am J Hypertension 2003;16:701–707.Google Scholar
  161. 161.
    McKee JA, Brewer RP, Macy GE, et al. Analysis of the brain bioavailability of peripherally administered magnesium sulfate: a study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. Crit Care Med 2005;33:661–666.PubMedGoogle Scholar
  162. 162.
    Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol 2007;6:29–38.PubMedGoogle Scholar
  163. 163.
    Maas AI, Murray GD. Magnesium for neuroprotection after traumatic brain injury. Lancet Neurol 2007;6: 20–21.PubMedGoogle Scholar
  164. 164.
    Heath DL, Vink R. Optimization of magnesium therapy after severe diffuse axonal brain injury in rats. J Pharmacol Exp Ther 1999;288:1311–1316.PubMedGoogle Scholar
  165. 165.
    Aslanyan S, Weir CJ, Muir KW, Lees KR; IMAGES Study Investigators. Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial. Stroke 2007;38:1269–1273.PubMedGoogle Scholar
  166. 166.
    Manet S, Marpeau L, Zupan-Simunek V, et al.; PREMAG Trial Group. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 2007;114:310–318.Google Scholar
  167. 167.
    Thal SC, Engelhard K, Werner C. New cerebral protection strategies. Curr Opin Anaesthesiol 2005;18:490–495.PubMedGoogle Scholar
  168. 168.
    Bhudia SK, Cosgrove DM, Naugle RI, et al. Magnesium as a neuroprotectant in cardiac surgery: a randomized clinical trial. J Thorac Cardiovasc Surg 2006;131:853–861.PubMedGoogle Scholar
  169. 169.
    Kaminska B, Gaweda-Walerych K, Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants: facts and hypotheses. J Cell Mol Med 2004;8:45–48.PubMedGoogle Scholar
  170. 170.
    Riess P, Bareyre FM, Saatman KE, et al. Effects of chronic, post-injury cyclosporin A administration on motor and sensorimotor function following severe, experimental traumatic brain injury. Restor Neurol Neurosci 2001;18:1–8.PubMedGoogle Scholar
  171. 171.
    Alessandri B, Rice AC, Levasseur J, DeFord M, Hamm RJ, Bullock RM. Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats. J Neurotrauma 2002;19:829–841.PubMedGoogle Scholar
  172. 172.
    Szabo I, Zoratti M. The giant channel of the inner mitochondrial membrane is inhibited by cyclosporin A. J Biol Chem 1991;266:3376–3379.PubMedGoogle Scholar
  173. 173.
    Sullivan PG, Thompson MB, Scheff SW. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp Neurol 1999;160:226–234.PubMedGoogle Scholar
  174. 174.
    Nakai A, Shibazaki Y, Taniuchi Y, Miyake H, Oya A, Takeshita T. Role of mitochondrial permeability transition in fetal brain damage in rats. Pediatr Neurol 2004;30:247–253.PubMedGoogle Scholar
  175. 175.
    Panickar KS, Jayakumar AR, Norenberg MD. Differential response of neural cells to trauma-induced free radical production in vitro. Neurochem Res 2002;27:161–166.PubMedGoogle Scholar
  176. 176.
    Mirzayan MJ, Klinge PM, Ude S, et al. Modified calcium accumulation after controlled cortical impact under cyclosporin A treatment: a 45Ca autoradiographic study. Neurol Res 2008;30:476–479.PubMedGoogle Scholar
  177. 177.
    Uchino H, Ishii N, Shibasaki F. Calcineurin and cyclophilin D are differential targets of neuroprotection by immunosuppressants CsA and FK506 in ischemic brain damage. Acta Neurochir Suppl 2003;86:105–111.PubMedGoogle Scholar
  178. 178.
    Mbye LH, Singh IN, Carrico KM, Saatman KE, Hall ED. Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J Cereb Blood Flow Metab 2008 Aug. 20 [Epub ahead of print].Google Scholar
  179. 179.
    Uchino H, Minamikawa-Tachino R, Kristian T, et al. Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. Neurobiol Dis 2002;10:219–233.PubMedGoogle Scholar
  180. 180.
    Domañska-Janik K, Buzañska L, Dłuzniewska J, Kozłowska H, Samowska A, Zabłocka B. Neuroprotection by cyclosporin A following transient brain ischemia correlates with the inhibition of the early efflux of cytochrome C to cytoplasm. Brain Res Mol Brain Res 2004;121:50–59.PubMedGoogle Scholar
  181. 181.
    Ferrand-Drake M, Zhu C, Gido G, et al. Cyclosporin A prevents calpain activation despite increased intracellular calcium concentrations, as well as translocation of apoptosis-inducing factor, cytochrome c and caspase-3 activation in neurons exposed to transient hypoglycemia. J Neurochem 2003;85:1431–1442.PubMedGoogle Scholar
  182. 182.
    Santos JB, Schauwecker PE. Protection provided by cyclosporin A against excitotoxic neuronal death is genotype specific. Epilepsia 2003;44:995–1002.PubMedGoogle Scholar
  183. 183.
    Van Den Heuvel C, Donkin JJ, Finnic JW, et al. Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration. J Neurotrauma 2004;21:1562–1572.Google Scholar
  184. 184.
    Okonkwo DO, Melon DE, Pellicane AJ, et al. Dose-response of cyclosporin A in attenuating traumatic axonal injury in rat. Neuro Report 2003;14:463–466.Google Scholar
  185. 185.
    Buki A, Okonkwo DO, Povlishock JT. Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J Neurotrauma 1999;16:511–521.PubMedGoogle Scholar
  186. 186.
    Okonkwo DO, Povlishock JT. An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J Cereb Blood Flow Metab 1999;19:443–451.PubMedGoogle Scholar
  187. 187.
    Okonkwo DO, Buki A, Siman R, Povlishock JT. Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. NeuroReport 1999;10:353–358.PubMedGoogle Scholar
  188. 188.
    Suehiro E, Singleton RH, Stone JR, Povlishock JT. The immunophilin ligand FK506 attenuated the axonal damage associated with rapid rewarming following posttraumatic hypothermia. Exp Neurol 2001;172:199–210.PubMedGoogle Scholar
  189. 189.
    Empey PE, McNamara PJ, Young B, Rosbolt MB, Hatton J. Cyclosporin A disposition following acute traumatic brain injury. J Neurotrauma 2006;23:109–116.PubMedGoogle Scholar
  190. 190.
    Mazzeo AT, Alves OL, Gilman CB, et al. Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study. Acta Neurochir (Wien) 2008;150:1019–1031.Google Scholar
  191. 191.
    Faden AI. Role of thyrotropin-releasing hormone and opiate receptor antagonists in limiting central nervous system injury. Adv Neurol 1988;47:531–546.PubMedGoogle Scholar
  192. 192.
    McIntosh TK, Vink R, Faden AI. An analog of thyrotropin-releasing hormone improves outcome after traumatic brain injury: 31P NMR studies. Am J Physiol 1988;254:R785-R792.PubMedGoogle Scholar
  193. 193.
    Vink R, McIntosh TK, Faden AI. Treatment with the thyrotropin-releasing hormone analog CG3703 restores magnesium homeostasis following traumatic brain injury in rats. Brain Res 1988;460:184–188.PubMedGoogle Scholar
  194. 194.
    Dewitt DS, Rough DS, Uchida T, Deal DD, Vines SM. Effects of nalmefene, CG3703, tirilazad, or dopamine on cerebral blood flow, oxygen delivery, and electroencephalographic activity after traumatic brain injury and hemorrhage. J Neurotrauma 1997;14:931–941.PubMedGoogle Scholar
  195. 195.
    Maejima S, Katayama Y. Neurosurgical trauma in Japan. World J Surg 2001;25:1205–1209.PubMedGoogle Scholar
  196. 196.
    Faden AI, Fox GB, Fan L, et al. Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents. Am J Physiol 1999;277:R1196-R1204.PubMedGoogle Scholar
  197. 197.
    Faden AI, Movsesyan VA, Knoblach SM, Ahmed F, Cernak I. Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacology 2005;49:410–424.PubMedGoogle Scholar
  198. 198.
    Niu GM, Gu XJ, Su YL, Wan F, Su FZ, Xue DL. Effect of thyrotropin-releasing hormone on cerebral free radical reactions following acute brain injury in rabbits. Chin J Traumatol 2003;6: 104–106.PubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2009

Authors and Affiliations

  1. 1.School of Medical SciencesUniversity of AdelaideAdelaideAustralia

Personalised recommendations